Applications of transcriptomics in support of drug development for osteoarthritis

Objective: Understanding the heterogeneity and pathophysiology of osteoarthritis (OA) is critical to support the development of tailored disease-modifying treatments. To this aim, transcriptomics tools are highly relevant to delineate dysregulated molecular pathways and identify new therapeutic targ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hélène Kaplon, Luo Yufei, Frédéric De Ceuninck, Agnès Lalande, Sophie Courtade-Gaiani, Laurence Laigle, Philippe Moingeon
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	DMOADs Molecular profiling Osteoarthritis Transcriptomics Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/4cf2075a13b540a8a40b0a21dab2775b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4cf2075a13b540a8a40b0a21dab2775b
record_format	dspace
spelling	oai:doaj.org-article:4cf2075a13b540a8a40b0a21dab2775b2021-11-22T04:30:41ZApplications of transcriptomics in support of drug development for osteoarthritis2665-913110.1016/j.ocarto.2021.100221https://doaj.org/article/4cf2075a13b540a8a40b0a21dab2775b2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2665913121000844https://doaj.org/toc/2665-9131Objective: Understanding the heterogeneity and pathophysiology of osteoarthritis (OA) is critical to support the development of tailored disease-modifying treatments. To this aim, transcriptomics tools are highly relevant to delineate dysregulated molecular pathways and identify new therapeutic targets. Methods: We review the methodology and outcomes of transcriptomics studies conducted in OA, based on a comprehensive literature search of the PubMed and Google Scholar databases using the terms “osteoarthritis”, “OA”, “knee OA”, “hip OA”, “genes”, “RNA-seq”, “microarray”, “transcriptomic” and “PCR” as key words. Beyond target-focused RT-qPCR, more comprehensive techniques include microarrays, RNA sequencing (RNA-seq) and single cell RNA-seq analyses. Results: The standardization of those methods to ensure the quality of both RNA extraction and sequencing is critical to get meaningful insights. Transcriptomics studies have been conducted in various tissues involved in the pathogenesis of OA, including articular cartilage, subchondral bone and synovium, as well as in the blood of patients. Molecular pathways dysregulated in OA relate to cartilage degradation, matrix and bone remodeling, neurogenic pain, inflammation, apoptosis and angiogenesis. This knowledge has direct application to patient stratification and further, to the identification of candidate therapeutic targets and biomarkers intended to monitor OA progression. Conclusion: In light of its high-throughput capabilities and ability to provide comprehensive information on major biological processes, transcriptomics represents a powerful method to support the development of new disease-modifying drugs in OA.Hélène KaplonLuo YufeiFrédéric De CeuninckAgnès LalandeSophie Courtade-GaianiLaurence LaiglePhilippe MoingeonElsevierarticleDMOADsMolecular profilingOsteoarthritisTranscriptomicsDiseases of the musculoskeletal systemRC925-935ENOsteoarthritis and Cartilage Open, Vol 3, Iss 4, Pp 100221- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	DMOADs Molecular profiling Osteoarthritis Transcriptomics Diseases of the musculoskeletal system RC925-935
spellingShingle	DMOADs Molecular profiling Osteoarthritis Transcriptomics Diseases of the musculoskeletal system RC925-935 Hélène Kaplon Luo Yufei Frédéric De Ceuninck Agnès Lalande Sophie Courtade-Gaiani Laurence Laigle Philippe Moingeon Applications of transcriptomics in support of drug development for osteoarthritis
description	Objective: Understanding the heterogeneity and pathophysiology of osteoarthritis (OA) is critical to support the development of tailored disease-modifying treatments. To this aim, transcriptomics tools are highly relevant to delineate dysregulated molecular pathways and identify new therapeutic targets. Methods: We review the methodology and outcomes of transcriptomics studies conducted in OA, based on a comprehensive literature search of the PubMed and Google Scholar databases using the terms “osteoarthritis”, “OA”, “knee OA”, “hip OA”, “genes”, “RNA-seq”, “microarray”, “transcriptomic” and “PCR” as key words. Beyond target-focused RT-qPCR, more comprehensive techniques include microarrays, RNA sequencing (RNA-seq) and single cell RNA-seq analyses. Results: The standardization of those methods to ensure the quality of both RNA extraction and sequencing is critical to get meaningful insights. Transcriptomics studies have been conducted in various tissues involved in the pathogenesis of OA, including articular cartilage, subchondral bone and synovium, as well as in the blood of patients. Molecular pathways dysregulated in OA relate to cartilage degradation, matrix and bone remodeling, neurogenic pain, inflammation, apoptosis and angiogenesis. This knowledge has direct application to patient stratification and further, to the identification of candidate therapeutic targets and biomarkers intended to monitor OA progression. Conclusion: In light of its high-throughput capabilities and ability to provide comprehensive information on major biological processes, transcriptomics represents a powerful method to support the development of new disease-modifying drugs in OA.
format	article
author	Hélène Kaplon Luo Yufei Frédéric De Ceuninck Agnès Lalande Sophie Courtade-Gaiani Laurence Laigle Philippe Moingeon
author_facet	Hélène Kaplon Luo Yufei Frédéric De Ceuninck Agnès Lalande Sophie Courtade-Gaiani Laurence Laigle Philippe Moingeon
author_sort	Hélène Kaplon
title	Applications of transcriptomics in support of drug development for osteoarthritis
title_short	Applications of transcriptomics in support of drug development for osteoarthritis
title_full	Applications of transcriptomics in support of drug development for osteoarthritis
title_fullStr	Applications of transcriptomics in support of drug development for osteoarthritis
title_full_unstemmed	Applications of transcriptomics in support of drug development for osteoarthritis
title_sort	applications of transcriptomics in support of drug development for osteoarthritis
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/4cf2075a13b540a8a40b0a21dab2775b
work_keys_str_mv	AT helenekaplon applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis AT luoyufei applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis AT fredericdeceuninck applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis AT agneslalande applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis AT sophiecourtadegaiani applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis AT laurencelaigle applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis AT philippemoingeon applicationsoftranscriptomicsinsupportofdrugdevelopmentforosteoarthritis
_version_	1718418158892613632

Applications of transcriptomics in support of drug development for osteoarthritis

Ejemplares similares